Anna Kochin, MD
Allergy · New York, NYNPI 1487804019
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Regeneron at 38.4% of the total. Reporting peaked in 2020 at $2,881 and has fallen 58.8% since, to $1,186 in 2025.
Across 157 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$671
- GSK$559
- AstraZeneca$341
- Optinose US, Inc.$129
- plus $1K from 27 others
What the payments were for
- Consulting fees$2,42537%
- Food & beverage$3,90459%
- Education$2534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $2,528 |
| Sanofi | 36 | $1,126 |
| Regeneron Healthcare Solutions, Inc. | 22 | $671 |
| GSK | 25 | $559 |
| AstraZeneca | 13 | $341 |
| Optinose US, Inc. | 6 | $129 |
| Boehringer Ingelheim | 6 | $122 |
| Pfizer | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| CSL Behring | 4 | $113 |
| Alk-abello, Inc | 3 | $89 |
| Novartis | 3 | $70 |
| Incyte Corporation | 3 | $68 |
| Pharming Healthcare, Inc. | 2 | $53 |
| Amarin Pharma, Inc. | 2 | $44 |
| Bayer | 2 | $39 |
| Biocryst US Sales Co., LLC | 1 | $37 |
| Phadia US Inc. | 2 | $35 |
| Genentech USA, Inc. | 1 | $34 |
| Exact Sciences | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Merck | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| LEO Pharma Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Grifols USA, LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,582 in reported general payments places this provider in the 70th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 154 | $294,288 |
| TezspireTezepelumab-Ekko | 37 | $185,996 |
| Dupixent SyringeDupilumab | 22 | $119,860 |
| EucrisaCrisaborole | 150 | $110,414 |
| Spiriva RespimatTiotropium Bromide | 61 | $29,469 |
| RyaltrisOlopatadine Hcl/Mometasone | 107 | $24,972 |
| SymbicortBudesonide/Formoterol Fumarate | 87 | $19,435 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,640 |
| Tacrolimus | 75 | $7,629 |
| AirsupraAlbuterol Sulfate/Budesonide | 15 | $6,609 |
| ZerviateCetirizine Hcl | 16 | $5,612 |
| Ketoconazole | 71 | $4,920 |
| Advair DiskusFluticasone Propion/Salmeterol | 26 | $4,446 |
| Azelastine Hcl | 227 | $4,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $68 | $294,288154 claims |
| AstraZenecaTezspire, Symbicort, Airsupra | $341 | $212,039139 claims |
| PfizerEucrisa | $116 | $110,414150 claims |
| Boehringer IngelheimSpiriva Respimat | $122 | $29,46961 claims |
| Hikma Pharmaceuticals USARyaltris | $21 | $24,972107 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $559 | $23,65151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 allergy providers in New York.
Other allergy in New York
- Sima PatelNew York$21K
- Mariana MarcuNew York$8K
- Gillian ShepherdNew York$7K
- Wellington TichenorNew York$3K
- Rushita MehtaNew York$694
- Lisa Ellman-GruntherNew York$627
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.